You have been asked to design a randomised controlled trial to compare a new SGLT-2 inhibitor called zetaglifozin against another SGLT-2 inhibitor already on the market, dapagliflozin.
You have been asked to design a randomised controlled trial to compare a new SGLT-2 inhibitor called zetaglifozin against another SGLT-2 inhibitor already on the market, dapagliflozin.
Which of the following is FALSE?
Take your subscriptions with you
Our mobile app allows you to access your interview and exam question banks wherever you are.